Non-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2

It is well known that NAFLD and T2DM occur commonly together. Prof Byrne (Southampton, UK) discusses the latest findings showing that NAFLD is an independent risk factor for cardiovascular events. The aetiology of increased risk of CVD is complex but the atherogenic dyslipidaemia is important. Genotypes can increase severity of liver disease and diabetes, yet attenuate risk of CVD.

Read More

Management of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D

Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.

Read More

Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)

Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression. Both PPARα-β/δ dual agonism as well as PPARγ agonism have shown beneficial effects on liver histology in phase IIb clinical trials for NASH.

Read More